Format

Send to

Choose Destination
J Thorac Oncol. 2018 Sep;13(9):1269-1283. doi: 10.1016/j.jtho.2018.06.011.

Scientific Advances and New Frontiers in Mesothelioma Therapeutics.

Author information

1
School of Environment and Life Sciences, College of Science and Technology, Cockcroft Building, University of Salford, Salford, United Kingdom.
2
Department of Pulmonary Medicine, Mayo Clinic, Rochester, Minnesota.
3
National Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia; Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
4
Pulmonary and Thoracic Oncology, CHU de Lille, Univ Lille, Lille, France; French National Network of Clinical Expert Centres for Malignant Pleural Mesothelioma Management.
5
Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.
6
Division of Thoracic Surgery, University of Toronto, Toronto, Ontario, Canada.
7
Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.
8
International Association for the Study of Lung Cancer, Aurora, Colorado.
9
International Association for the Study of Lung Cancer, Aurora, Colorado; Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado.
10
Thoracic Oncology, University of Hawaii Cancer Center, Honolulu, Hawaii.
11
Development Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
12
Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland. Electronic address: hassanr@mail.nih.gov.

Abstract

Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer that arises from the mesothelial surface of the pleural and peritoneal cavities, the pericardium, and rarely, the tunica vaginalis. The incidence of MPM is expected to increase worldwide in the next two decades. However, even with the use of multimodality treatment, MPM remains challenging to treat, with a 5-year survival rate of less than 5%. The International Association for the Study of Lung Cancer has gathered experts in different areas of mesothelioma research and management to summarize the most significant scientific advances and new frontiers related to mesothelioma therapeutics.

KEYWORDS:

Biomarkers; Chemotherapy; Immunotherapy; Malignant pleural mesothelioma; Oncology therapeutics

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center